Downloads: 513
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Kanai_2010_Cancer Epidemiology.pdf | 265.34 kB | Adobe PDF | View/Open |
Title: | Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. |
Authors: | Kanai, Masashi ![]() ![]() Yoshioka, Akira Tanaka, Shiro ![]() ![]() ![]() Nagayama, Satoshi Matsumoto, Shigemi ![]() ![]() Nishimura, Takafumi Niimi, Miyuki Teramukai, Satoshi Takahashi, Ryo ![]() ![]() Mori, Yukiko ![]() ![]() Kitano, Toshiyuki ![]() ![]() Ishiguro, Hiroshi ![]() ![]() Yanagihara, Kazuhiro Chiba, Tsutomu ![]() ![]() Fukushima, Masanori Matsuda, Fumihiko ![]() ![]() |
Author's alias: | 金井, 雅史 |
Keywords: | Oxaliplatin Neurotoxicity Colorectal cancer GSTP1 Ile105Val AGXT Pro11Leu AGXT Ile340Met |
Issue Date: | Apr-2010 |
Journal title: | Cancer epidemiology |
Volume: | 34 |
Issue: | 2 |
Start page: | 189 |
End page: | 193 |
Abstract: | PURPOSE: Although the risk of oxaliplatin-induced neuropathy depends on cumulative oxaliplatin dose, susceptibility to this adverse event differs greatly among patients. In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met. EXPERIMENTAL DESIGN: Eighty-two Japanese patients with histologically confirmed colorectal cancer who received at least six cycles of the modified FOLFOX6 (m-FOLFOX6) regimen were enrolled. To minimize differences in cumulative oxaliplatin dose between patients, oxaliplatin-induced neuropathy was evaluated using an oxaliplatin-specific scale during the 2-week period after completion of the sixth cycle of treatment. RESULTS: Forty-four patients developed grade 2/3 oxaliplatin-induced neuropathy. There were more patients carrying at least one GSTP1(105)Val allele among the group with grade 2/3 neuropathy (18/44, 41%) than among the group with grade 1 neuropathy (9/38, 24%), although the difference was not statistically significant (P=0.098). There were similar numbers of patients carrying at least one AGXT(105)Met allele in the grade 2/3 neuropathy (7/44, 16%) and grade 1 neuropathy groups (5/38, 13%; P=0.725). The AGXT(11)Leu allele was not found in any of our patients or controls. CONCLUSIONS: We found no significant association between oxaliplatin-induced neuropathy and the GSTP1 Ile(105)Val and AGXT Ile(340)Met polymorphisms. Given that no AGXT(11)Leu allele was found among our study population (n=177), evaluating this polymorphism in Japanese patients in future studies is likely to be uninformative. |
Rights: | © 2010 Elsevier この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version. |
URI: | http://hdl.handle.net/2433/109963 |
DOI(Published Version): | 10.1016/j.canep.2010.02.008 |
PubMed ID: | 20308030 |
Appears in Collections: | Journal Articles |

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.